Arbutus Biopharma Corporation ABUS Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's accounts payable and other current liabilities (note 11)?
- Arbutus Biopharma Corporation (ABUS) reported accounts payable and other current liabilities (note 11) of $4.47M in Q1 2026.
- How has Arbutus Biopharma Corporation's accounts payable and other current liabilities (note 11) changed year-over-year?
- Arbutus Biopharma Corporation's accounts payable and other current liabilities (note 11) decreased by 63.1% year-over-year, from $12.11M to $4.47M.
- What is the long-term trend for Arbutus Biopharma Corporation's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's accounts payable and other current liabilities (note 11) has grown at a -9.8% compound annual growth rate (CAGR), from $9.15M to $5.46M.